Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in secondary and exploratory measures.